VVelarionINTELLIGENCE
Sign inStart free trial
Start free trial
Biopharma & Life Sciences

Adverum Biotechnologies Executive Compensation (FY24)

ADVM · Executive and director compensation, fiscal 2022 to 2024
Chief executive, fiscal 2024
◇
Laurent Fischer
Chief executive pay ratio
◇
To the median employee
Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.

The Adverum Biotechnologies brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
Data as of October 25, 2026Latest filing (DEF 14A): April 28, 2025
1 filing cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Adverum Biotechnologies brief$1,500Get the executive brief
Velarion Intel, one year, every company
162 figures on this page, cited to the filing that reported them. See the citations
What changed from fiscal 2023 to fiscal 2024
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Laurent Fischer: $1,546,477 → $4,131,290 (167.1% higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Adverum Biotechnologies' chief executive and what were they paid?
Total compensation for Laurent Fischer, President and Chief Executive Officer, came to $4,131,290 in fiscal 2024. Fischer's total was 167.1% higher than the $1,546,477 reported for fiscal 2023.
Which companies are in Adverum Biotechnologies' peer group?
The disclosed peer group names 4D Molecular Therapeutics, Aldeyra Therapeutics, Allakos, Allovir and Assembly Biosciences, among others. The 2025 Peer Group includes Alector, EyePoint Pharmaceuticals, Kodiak Sciences, Nkarta and Ocular Therapeutics.
What is Adverum Biotechnologies' chief executive pay ratio?
The disclosed chief executive pay ratio for fiscal 2024 is 19:1, against median employee compensation of $212,303.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Laurent Fischer
President and Chief Executive Officer
◇——◇◇—◇◇
Setareh Seyedkazemi
Chief Development Officer
◇◇◇◇◇—◇◇
Kishor Peter Soparkar
Chief Operating Officer
◇——◇◇—◇◇
Linda Rubinstein
Chief Financial Officer
——————◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Linda Rubinstein
Chief Financial Officer
◇——◇◇—◇◇
Laurent Fischer
President and Chief Executive Officer
◇——◇◇—◇◇
Kishor Peter Soparkar
Chief Operating Officer
◇——◇◇—◇◇
Setareh Seyedkazemi
Chief Development Officer
◇——◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Laurent Fischer
President and Chief Executive Officer
◇—◇◇◇—◇◇
Kishor Soparkar
Chief Operating Officer
◇—◇◇◇—◇◇
Linda Rubinstein
Chief Financial Officer
◇——◇◇—◇◇
Setareh Seyedkazemi
Chief Development Officer
◇—◇◇◇—◇◇
Rabia Ozden
Chief Medical Officer
◇◇—◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2024 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Laurent FischerOption◇—◇8/1/2034
Option◇—◇2/11/2034
Option◇—◇2/28/2033
PSU◇◇——
Option◇—◇3/7/2032
Option◇—◇9/13/2032
Option◇—◇3/7/2032
Option◇—◇2/16/2031
Rabia OzdenOption◇—◇6/16/2034
Option◇—◇8/1/2034
Option◇—◇3/16/2032
Kishor SoparkarOption◇—◇8/1/2034
Option◇—◇2/11/2034
Option◇—◇2/28/2033
PSU◇◇——
Option◇—◇3/7/2032
Option◇—◇3/7/2032
Option◇—◇9/13/2032
Option◇—◇2/15/2031
Linda RubinsteinOption◇—◇8/1/2034
Option◇—◇8/2/2033
Option◇—◇2/11/2034
Setareh SeyedkazemiOption◇—◇8/1/2034
Option◇—◇2/11/2034
Option◇—◇2/28/2033
Option◇—◇1/5/2032
PSU◇◇——
Option◇—◇3/7/2032
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2024
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Patrick Machado
Board chair
◇—◇———◇
Szilard Kiss
◇—◇——◇◇
James Scopa
◇—◇———◇
Scott Whitcup
◇—◇———◇
Dawn Svoronos
◇—◇———◇
Mark Lupher
◇—◇———◇
Reed Tuckson
◇—◇———◇
C. David Nicholson
◇—◇———◇
Soo Hong
◇—◇———◇
Laurent Fischer served on the board in fiscal 2024 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as Options.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2024
  • 4D Molecular Therapeutics FDMT
  • Aldeyra Therapeutics ALDX
  • Allakos ALLK
  • Allovir KLRS
  • Assembly Biosciences ASMB
  • CytomX Therapeutics CTMX
  • Generation Bio Co. GBIO
  • Lineage Cell Therapeutics LCTX
  • MeiraGTx MGTX
  • Ovid Therapeutics OVID
  • RAPT Therapeutics RAPT
  • Solid Biosciences SLDB
  • Syros Pharmaceuticals SYRS
  • Taysha Gene Therapies TSHA
  • Tenaya Therapeutics TNYA
  • Voyager Therapeutics VYGR
2025 Peer Group
  • Alector ALEC
  • EyePoint Pharmaceuticals EYPT
  • Kodiak Sciences KOD
  • Nkarta NKTX
  • Ocular Therapeutics OCUL

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Laurent Fischer (President and Chief Executive Officer), FY2024 total compensation $4,131,290 (base salary $691,795) [exec_comp, SEC accession 0001140361-25-016005, filed 2025-04-28]

See a complete sample report

Answered within 24 hours, every figure cited to its SEC filing. This is a one-off report: no refunds.

Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Adverum Biotechnologies files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Adverum Biotechnologies disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Adverum Biotechnologies sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Adverum Biotechnologies' disclosed peer group is defensible, who names Adverum Biotechnologies back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
162 figures on this page, cited to the filing that reported them.
162 cited to the filing

Documents cited

  1. 0001140361-25-016005
    NON-EMPLOYEE DIRECTOR COMPENSATION · PAY RATIO DISCLOSURE
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Adverum Biotechnologies executive compensation, FY2022–FY2024.” https://intel.velarion.ai/comp/ADVM (accessed 2026).
Short form: data: Velarion

The Adverum Biotechnologies brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
1 filing cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Adverum Biotechnologies and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Adverum Biotechnologies discloses

The companies named in ADVM's own disclosed peer group.

4D Molecular TherapeuticsAldeyra TherapeuticsAllakosAllovirAssembly BiosciencesCytomX TherapeuticsGeneration Bio Co.Lineage Cell TherapeuticsMeiraGTxOvid TherapeuticsRAPT TherapeuticsSolid BiosciencesSyros PharmaceuticalsTaysha Gene TherapiesTenaya TherapeuticsVoyager TherapeuticsAlectorEyePoint PharmaceuticalsKodiak SciencesNkartaOcular Therapeutics

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy